Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aaron D. Krabill has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Daniel P. Flaherty

    Borch Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States

    5 shared publications
  • Ahmed Elkashif

    Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, 625 Harrison Street, West Lafayette, Indiana 47907, United States

    2 shared publications
  • Amanda L. Graboski

    Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, Indiana 47907, United States

    2 shared publications
  • Chittaranjan Das

    Department of Chemistry Purdue University 560 Oval Dr. West Lafayette IN 47907 USA

    2 shared publications
  • Hao Chen

    School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China

    2 shared publications
  • Jatinder Kaur

    Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, Indiana 47907, United States

    2 shared publications

Latest Publications

  • Functional interrogation and therapeutic targeting of protein tyrosine phosphatases

    by Aaron D. Krabill, Zhong-Yin Zhang

    Protein tyrosine phosphatases (PTPs) counteract the enzymatic activity of protein tyrosine kinases to modulate levels of both normal and disease-associated protein tyrosine phosphorylation. Aberrant activity of PTPs has been linked to the progression of many disease states, yet no PTP inhibitors are currently clinically available. PTPs are without a doubt a difficult drug target. Despite this, many selective, potent, and bioavailable PTP inhibitors have been described, suggesting PTPs should once again be looked at as viable therapeutic targets. Herein, we summarize recently discovered PTP inhibitors and their use in the functional interrogation of PTPs in disease states. In addition, an overview of the therapeutic targeting of PTPs is described using SHP2 as a representative target.


  • Structure–Activity Relationship Studies of Acetazolamide-Based Carbonic Anhydrase Inhibitors with Activity against Neisseria gonorrhoeae

    by Chad S. Hewitt, Nader S. Abutaleb, Ahmed E. M. Elhassanny, Alessio Nocentini, Xufeng Cao, Devon P. Amos, Molly S. Youse, Katrina J. Holly, Anil Kumar Marapaka, Weiwei An, et al.

    Neisseria gonorrhoeae is an urgent threat to public health in the United States and around the world. Many of the current classes of antibiotics to treat N. gonorrhoeae infection are quickly becoming obsolete due to increased rates of resistance. Thus, there is a critical need for alternative antimicrobial targets and new chemical entities. Our team has repurposed the FDA-approved carbonic anhydrase inhibitor scaffold of acetazolamide to target N. gonorrhoeae and the bacteria’s essential carbonic anhydrase, NgCA. This study established both structure–activity and structure–property relationships that contribute to both antimicrobial activity and NgCA activity. This ultimately led to molecules 20 and 23, which displayed minimum inhibitory concentration values as low as 0.25 μg/mL equating to an 8- to 16-fold improvement in antigonococcal activity compared to acetazolamide. These analogues were determined to be bacteriostatic against the pathogen and likely on-target against NgCA. Additionally, they did not exhibit any detrimental effects in cellular toxicity assays against both a human endocervical (End1/E6E7) cell line or colorectal adenocarcinoma cell line (Caco-2) at concentrations up to 128 μg/mL. Taken together, this study presents a class of antigonococcal agents with the potential to be advanced for further evaluation in N. gonorrhoeae infection models.


  • Open Access

    Optimization and Anti-Cancer Properties of Fluoromethylketones as Covalent Inhibitors for Ubiquitin C-Terminal Hydrolase L1

    by Aaron D. Krabill, Hao Chen, Sajjad Hussain, Chad S. Hewitt, Ryan D. Imhoff, Christine S. Muli, Chittaranjan Das, Paul J. Galardy, Michael K. Wendt, Daniel P. Flaherty

    The deubiquitinating enzyme (DUB) UCHL1 is implicated in various disease states including neurodegenerative disease and cancer. However, there is a lack of quality probe molecules to gain a better understanding on UCHL1 biology. To this end a study was carried out to fully characterize and optimize the irreversible covalent UCHL1 inhibitor VAEFMK. Structure-activity relationship studies identified modifications to improve activity versus the target and a full cellular characterization was carried out for the first time with this scaffold. The studies produced a new inhibitor, 34, with an IC50 value of 7.7 µM against UCHL1 and no observable activity versus the closest related DUB UCHL3. The molecule was also capable of selectively inhibiting UCHL1 in cells and did not demonstrate any discernible off-target toxicity. Finally, the molecule was used for initial probe studies to assess the role of UCHL1 role in proliferation of myeloma cells and migration behavior in small cell lung cancer cells making 34 a new tool to be used in the biological evaluation of UCHL1.


  • Development of Ubiquitin Variants with Selectivity for Ubiquitin C-Terminal Hydrolase Deubiquitinases

    by Chad S. Hewitt, Aaron D. Krabill, Chittaranjan Das, Daniel P. Flaherty

    Ubiquitin (Ub) is a small highly conserved protein that is covalently attached to substrate proteins as a post translational modification to regulate numerous signaling pathways such as proteasomal degradation and cell cycle/transcriptional regulation in the eukaryotic cellular environment. The role of Ub as a post-translational signal in these pathways results in a highly regulated homeostasis of substrate protein ubiquitination/deubiquitination by E3 ligases and deubiquitinating enzymes (DUB) in healthy eukaryotic systems. One such DUB known as Ubiquitin C-terminal Hydrolase L1 (UCHL1) is endogenously expressed in the central nervous system under normal physiological conditions but overexpression and/or mutation has been linked to various cancers and neurodegenerative diseases. There is a significant lack of UCHL1 probing strategies and development of a selective Ub-variant (UbV) to probe UCHL1’s role in these disease states would be immensely beneficial. To this end, we describe a rational design approach to investigate Ub mutants that lend selectivity to UCHL1 over the close structural homolog UCHL3 and other DUB families. UbT9F/T66K displayed appreciable selectivity for recombinantly expressed UCHL1 over UCHL3 compared to WT-Ub in in vitro assays. By appending a reactive electrophile to the C-terminus of the Ub mutant we created the first activity-based probe (ABP) with demonstrated selectivity for UCH family DUBs over other families in cell lysates. Further analysis of kinetics of covalent inhibition by the UbV-ABP with UCHL1 and UCHL3 offers insight into future design toward UCHL1-selective Ub-ABP probe for applications in the cellular environment. These studies serve as a proof-of-concept of the viability of in silico rational design of ubiquitin variants for UCH family DUBs as a step toward the development macromolecular UCHL1 inhibitors.


  • Optimization of Acetazolamide-Based Scaffold as Potent Inhibitors of Vancomycin-Resistant Enterococcus

    by Jatinder Kaur, Xufeng Cao, Nader S. Abutaleb, Ahmed Elkashif, Amanda L. Graboski, Aaron D. Krabill, Ahmed Hassan AbdelKhalek, Weiwei An, Atul Bhardwaj, Mohamed N. Seleem, et al.

    Vancomycin-resistant enterococci (VRE) are the second leading cause of hospital-acquired infections (HAIs) attributed to a drug-resistant bacterium in the United States, and resistance to the frontline treatments is well documented. To combat VRE, we have repurposed the FDA-approved carbonic anhydrase drug acetazolamide to design potent antienterococcal agents. Through structure–activity relationship optimization we have arrived at two leads possessing improved potency against clinical VRE strains from MIC = 2 μg/mL (acetazolamide) to MIC = 0.007 μg/mL (22) and 1 μg/mL (26). Physicochemical properties were modified to design leads that have either high oral bioavailability to treat systemic infections or low intestinal permeability to treat VRE infections in the gastrointestinal tract. Our data suggest the intracellular targets for the molecules are putative α-carbonic and γ-carbonic anhydrases, and homology modeling and molecular dynamics simulations were performed. Together, this study presents potential anti-VRE therapeutic options to provide alternatives for problematic VRE infections.


  • Ubiquitin C‐Terminal Hydrolase L1: Biochemical and Cellular Characterization of a Covalent Cyanopyrrolidine‐Based Inhibitor

    by Aaron D. Krabill, Hao Chen, Sajjad Hussain, Chao Feng, Ammara Abdullah, Chittaranjan Das, Uma K. Aryal, Carol Beth Post, Michael K. Wendt, Paul J. Galardy, et al.

    The deubiquitinase (DUB) ubiquitin C‐terminal hydrolase L1 (UCHL1) is expressed primarily in the central nervous system under normal physiological conditions. However, UCHL1 is overexpressed in various aggressive forms of cancer with strong evidence supporting UCHL1 as an oncogene in lung, glioma, and blood cancers. In particular, the level of UCHL1 expression in these cancers correlates with increased invasiveness and metastatic behavior, as well as poor patient prognosis. Although UCHL1 is considered an oncogene with potential as a therapeutic target, there remains a significant lack of useful small‐molecule probes to pharmacologically validate in vivo targeting of the enzyme. Herein, we describe the characterization of a new covalent cyanopyrrolidine‐based UCHL1 inhibitory scaffold in biochemical and cellular studies to better understand the utility of this inhibitor in elucidating the role of UCHL1 in cancer biology.